Impact of COVID‑19 in the incidence of venous thromboembolism (VTE) and clinical outcomes in cancer patients: a cohort study
-
Carlos López Jiménez [1] ; Ana Gutiérrez [1] ; David Salomón Juliao Caamaño [1] ; Javier Soto Alsar [1] ; Juan Luis Catoya Villa [2] ; Carmen Blanco Abad [3] ; Blanca Morón [4] ; Laura Ortega Morán [1] ; Miguel Martín [1] ; Andrés Jesús Muñoz Martín [1]
-
[1] Hospital General Universitario Gregorio Marañón
Hospital General Universitario Gregorio Marañón
Madrid, España
-
[2] Hospital Universitario 12 de Octubre
Hospital Universitario 12 de Octubre
Madrid, España
-
[3] Hospital Miguel Servet
Hospital Miguel Servet
Zaragoza, España
-
[4] Hospital Ramón y Cajal
Hospital Ramón y Cajal
Madrid, España
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 27, Nº. 2, 2025, págs. 756-769
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Purpose To determine the incidence of VTE and clinical outcomes in a cohort of cancer patients and COVID-19 infection, and to establish possible predictive factors of VTE.
Methods/patients A single-center retrospective cohort study was performed to determine the incidence of VTE and mortality in 118 cancer patients with SARS-CoV-2 infection from March to August 2020. We calculated individual Khorana Risk and CATS-MICA scores in order to evaluate their utility to identify risk of VTE or death. Continuous variables were compared using Wilcoxon or Student’s T test, and categorical variables were compared using the Chi-Square or Fisher’s exact text among patients with and without VTE. A Log-Rank test was performed to detect mortality differences between the groups.
Results A total of 118 patients were included. VTE global incidence was 4.2% (n = 5), and mortality 25.4% (n = 30). Obesity (p = 0.05), recent chemotherapy (p = 0.049) and use of steroids (p = 0.006) were related to higher risk of VTE in the univariate analysis, although they were not confirmed in the multivariate analysis as independent risk factors. Statistically significant differences in all-cause, COVID-19-related and cancer-related mortality according to the Khorana risk score (KRS) were observed. CATS-MICA score (CMS) also showed statistically significant differences in mortality between low- and high-risk patients. Prediction of risk of VTE development with these scores showed a tendency towards significance.
Conclusions In this cohort, VTE incidence was similar to previously reported in the general population with SARS-CoV-2 infection. KRS was associated with overall and specific-cause mortality, and might be a useful prognostic tool in this setting.
